| Product Unit Size | Cost | Quantity | Stock |
|---|
OTS-964 is an inhibitor of T-lymphokine-activated killer cell-originated protein kinase (TOPK). This kinase plays an integral role in the mitosis of cancer cells, including lung and triple negative breast cancers. OTS-964 induces apoptosis in cancer cells in vitro and in xenograft models of human lung cancer. It also exhibits efficacy in controlling the regrowth of glioma stem cell populations, limiting recurrence.
| Cas No. | 1338545-07-5 |
|---|---|
| Purity | ≥98% |
| Formula | C22H22N2O2S |
| Formula Wt. | 378.49 |
| Chemical Name | OTS-964 |
| IUPAC Name | 9-{4-[(2R)-1-(Dimethylamino)-2-propanyl]phenyl}-8-hydroxythieno[2,3-c]quinolin-4(5H)-one |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Matsuo Y., Park J., et al. TOPK inhibitor induces complete tumor regression in xenograft models of human cancer through inhibition of cytokinesis. Sci Transl Med. 6(250):269ra145 (2014). PMID: 25338756.
Sugimori M., Hayakawa Y., et al. The combined efficacy of OTS964 and temozolomide for reducing the size of power-law coded heterogeneous glioma stem cell populations. Oncotarget. 10(24):2397-2415 (2019). PMID: 31040930.